Home secretary Sajid Javid has announced a review of medicinal cannabis in the UK, in response to growing pressure to allow use of cannabis oil to help control seizures in children with severe forms ...

Japanese pharma company Astellas has completed its 800 million euro acquision of Ogeda. The Beligium biotech is now a wholly-owned subsidiary of Astellas and expands the firm’s late-stage pipeline.

Destiny Pharma has been awarded a significant new grant funding up to £1.6 million, under the new UK-China antimicrobial resistance (AMR) programme. Destiny Pharma has been awarded a significant new ...

Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside ...

Drug-resistant superbugs are on the rise worldwide and represent a threat to global public health and health security. Oxford Drug Design has received over £8 million in grant and equity investment ...

The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug. The NHS is set to save a record £300 million ...

The former president of AstraZeneca UK and the ABPI has given up big pharma to join biotech Redx. We speak to her about what prompted the change, how she thinks British life science will fare in the ...

Storm Beadle has joined Cognite, the international Strategy and Communications agency based in London and Zurich. Storm, who joins as a Senior Account Manager, left university with a degree focused on ...

Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US. Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the ...

The latest GP workforce figures show a small rise in numbers, which the Royal College of General Practitioners (RCGP) says must be “sustained and accelerated”. The latest GP workforce figures show a ...

Roche’s Kadcyla (trastuzumab emtansine)should soon be available on the NHS as a treatment option for patients with HER2-positive early breast cancer having won the backing of the National Institute ...

The European Medicines Agency’s (EMA) committee for Medicinal Products for Human Use (CHMP) recommended 15 new medicines for approval in its final meeting of the year. First to score a recommendation ...